ULK-101 is primarily investigated for its potential in cancer therapy, specifically targeting autophagy pathways. Autophagy, a cellular process that degrades and recycles damaged components, is often dysregulated in cancer cells. By modulating autophagy, ULK-101 aims to inhibit tumor growth and enhance the efficacy of other cancer treatments. Researchers are exploring its use in combination with chemotherapy or radiation to improve outcomes in resistant cancers. Additionally, its role in neurodegenerative diseases is being studied, as autophagy plays a critical part in clearing toxic protein aggregates. The compound’s ability to selectively target specific cellular mechanisms makes it a promising candidate for therapeutic development in various diseases.